Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.
Also called NCT04824911
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 376 participants
- Sponsor
- Registry
-
NCT04824911
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04824911. Non-randomized; no masking; primary purpose treatment. Start 2021-03-23 (actual); primary completion 2025-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
- Acronym
- SATBRAD
- Condition
- Acute Stroke
- Condition
- Dual Antiplatelet Therapy
- Condition
- Statin
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Rosuvastatin
- Lead sponsor
- Chang Gung Memorial Hospital
Record details
- Record id
cardio:ct-nct04824911- Content hash
ac9d0a066f20870338a3844c50156ebb3414ada8352d136de5540ed2beea8284